| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2014 | Dec, 2013 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,890 | -1,610 | -2,650 | -9,380 | -8,800 |
| Net Income Growth | -17.39% | +39.25% | +71.75% | -6.59% | +39.31% |
Eom Pharmaceutical Holdings Inc (IMUC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
EOM Pharmaceuticals Inc. is a privately held, clinical-stage pharmaceutical company. It focus on advancing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal and other diseases. EOM Pharmaceuticals Inc., formerly known as ImmunoCellular Therapeutics Ltd., is based in MONTVALE, N.J.
Fiscal Year End Date: 12/31